<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332264</url>
  </required_header>
  <id_info>
    <org_study_id>SP01</org_study_id>
    <nct_id>NCT03332264</nct_id>
  </id_info>
  <brief_title>Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions</brief_title>
  <acronym>SPORTS</acronym>
  <official_title>Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnoRa GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>InnoRa GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with peripheral artery disease will be treated with either drug coated balloon
      catheter, drug coated stent or uncoated stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic stenotic or occlusive atherosclerotic disease and lesions of at least
      13 cm length in the SFA or Arteria poplitea segment 1 will be randomized to either treatment
      with paclitaxel coated balloon catheter, paclitaxel coated stent or bare nitinol stent.
      Vessel patency will be evaluated by quantitative angiography after 12 months. Clinical
      follow-ups will be done until 36 months post-intervention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Vessel patency will be compared by quantitative angiography at 12 months in patients who have been treated either with paclitaxel coated balloon catheter, paclitaxel coated stent or bare metal stent in femoropopliteal arteries</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Corelab will be masked for the bare metal and paclitaxel coated stent arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent diameter stenosis at 1 year post intervention in successfully treated patients</measure>
    <time_frame>12 +/- 2 months</time_frame>
    <description>by quantitative angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss</measure>
    <time_frame>12 months</time_frame>
    <description>by quantitative angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis</measure>
    <time_frame>6,12, 24, 36 months</time_frame>
    <description>by DUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>number of re-interventions at target lesion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Event-free survival</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>absence from target lesion revascularization, amputations and death</description>
  </other_outcome>
  <other_outcome>
    <measure>Walking distance</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>assessed in m and compared to baseline value</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Stenosis</condition>
  <condition>Occlusion</condition>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>Drug coated balloon catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTA with paclitaxel coated &quot;SeQuent Please OTW&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug coated stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTA with paclitaxel coated &quot;Eluvia Vascular Stent System&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncoated stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTA with bare nitinol stent (as commonly used in site)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeQuent Please OTW</intervention_name>
    <description>Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter</description>
    <arm_group_label>Drug coated balloon catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eluvia Vascular Stent System</intervention_name>
    <description>Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent</description>
    <arm_group_label>Drug coated stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nitinol stent</intervention_name>
    <description>Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent</description>
    <arm_group_label>Uncoated stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PAOD and Rutherford classes 2 - 4 (pain-free walking distance &lt;500 m)

          -  eligible for peripheral revascularization by means of PTA

          -  peripheral lesions in the superficial femoral artery (SFA) and / or the PI-segment of
             the popliteal artery (A.pop.)

          -  minimum diameter stenosis of ≥70%

          -  treatment length at least 15 cm (lesion length at least 13 cm)

          -  maximum of lesions to be treated should be 2 (all treated lesions should be treated
             within the randomization to the study group, i.e. either coated balloon catheters or
             coated stents or bare nitinol stents); in case of two lesions matching the eligibility
             criteria, the one presenting the worst attributes (length and stenosis degree) should
             be chosen as target lesion

          -  long diffuse stenosis with or without occlusions may only be divided in separate
             lesions if non-stenotic (i.e. &lt;50% stenosis) segments in between the lesions extent to
             &gt;2 cm, otherwise vessel segments will be treated as a single extended lesion

          -  eligible for an operative vascular intervention in case of complications during the
             PTA

        Exclusion Criteria:

          -  Rutherford class 1,5 or 6

          -  more than two stenotic lesions in the target vessel requiring treatment

          -  inflow lesion (proximal to the study lesion) with flow limitation not being
             successfully treated prior to the study lesion

          -  in-stent restenosis of the study lesion

          -  strongly calcified lesions with circumferential presence of calcifications and a
             lesion calcification length of &gt;4 cm

          -  reference vessel diameter &lt;4 mm and &gt;6 mm

          -  guide wire could not be successfully advanced across the lesion

          -  lesions below the knee requiring treatment

          -  target lesion is located in the PII-segment of the popliteal artery (A.pop.) or within
             a bypass graft

          -  acute thrombosis of the study lesion requiring lysis or thrombectomy prior to the
             treatment of the study lesion

          -  potential loss of leg due to critical or acute ischemia

          -  no patent distal run-off vessel

          -  medical reason against double anti-platelet therapy in anti-coagulated patient, e.g.,
             receiving coumarine or conditions which prevent the intake of the double anti-platelet
             therapy for two months

          -  female patient who is pregnant or lactating

          -  under 18 years of age

          -  patients under administrative or judicial custody (§20 Act on medical Devices,
             Germany)

          -  expected life span of less than 24 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Tepe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RoMed Klinikum Rosenheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maren Kutschera, PhD</last_name>
    <phone>+4930 8574117 14</phone>
    <email>maren.kutschera@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatrix Schnorr, DVM</last_name>
    <email>beatrix.schnorr@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RoMed Klinikum</name>
      <address>
        <city>Rosenheim</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Tepe, MD</last_name>
      <phone>+4980313653551</phone>
    </contact>
    <investigator>
      <last_name>Gunnar Tepe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Arnsberg, Karolinen-Hospital</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lichtenberg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Lichtenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Zeller, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Zeller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ihre-Radiologen Standort Franziskus-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Brechtel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Klaus Brechtel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ihre-Radiologen Standort Jüdisches Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Schröder, MD</last_name>
    </contact>
    <investigator>
      <last_name>Henrik Schröder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Flensburg</name>
      <address>
        <city>Flensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Müller-Hülsbeck, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Müller-Hülsbeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan P. Goltz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jan P. Goltz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAOD</keyword>
  <keyword>drug coated balloon</keyword>
  <keyword>drug coated stent</keyword>
  <keyword>percutaneous transluminal angioplasty (PTA)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

